Navigation Links
New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment
Date:12/15/2007

SAN ANTONIO, Dec. 15 /PRNewswire/ -- Denosumab is a new drug being studied to prevent fractures in breast cancer patients receiving hormonal therapy. Results of a phase 3 clinical trial using denosumab were presented Friday evening at the San Antonio Breast Cancer Symposium by Georgiana Ellis, MD, from the Seattle Cancer Care Alliance.

Denosumab is a highly specific antibody that interrupts the development of osteoclasts -- specialized cells that break down bone. Because it is highly specific, the chance of systemic effects in other parts of the body is low, so patients do not need routine laboratory monitoring.

A group of drugs called aromatase inhibitors is used to prevent the recurrence of breast cancer in postmenopausal women. These drugs are very effective, but commonly associated with loss of bone density and an increased risk of fractures.

To test the effectiveness of denosumab in preventing bone loss caused by aromatase inhibitors, a clinical trial recruited 252 patients who had been treated for early stage breast cancer and for whom treatment with anastrozole, an aromatase inhibitor, was planned. Half of the patients were given denosumab, while the other half was not. All patients were instructed to take daily doses of calcium and vitamin D.

The study lasted for 2 years, with patients receiving an injection of denosumab every 6 months. All the women from both groups had their lumbar spine bone density measured at the end of the first and second years. By the end of the first year, the bone density of the women receiving denosumab had increased by nearly 5%, while the women who did not receive denosumab had bone density decreases of almost 1%. By the end of the second year, the difference was even greater: in the women receiving denosumab, bone density had increased by almost 6%, while the bone density of the women who did not receive denosumab decreased by nearly 2%. Similar effects on bone density were seen at the hip and the wrist. Side effects of denosumab were similar to those reported in the control group.

Denosumab appears to be a safe and effective treatment for preventing bone loss in women taking aromatase inhibitors, offering an alternative to existing therapies, such as oral or intravenous bisphosphonates.


'/>"/>
SOURCE San Antonio Breast Cancer Symposium
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Flash Technology Prevents Pain From Carpal Tunnel Syndrome
2. International Atomic Energy Agency and National Foundation for Cancer Research Launch Major Initiative to Improve Cancer Prevention and Treatments in Developing Countries
3. New White Paper Details Six Steps to Investigate and Prevent Laboratory Accidents
4. Protherics UK Ltd. Chooses TrackWise for Corrective Action and Preventive Action (CAPA) Management
5. Leading Edge Research Underway in Fall Prevention for Seniors
6. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
7. Individual differences caused by shuffled chunks of DNA in the human genome
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
10. Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
11. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Febr. 10, 2016 /PRNewswire/ - BioAmber Inc. (NYSE: ... to announce that Mitsui & Co. Ltd., its partner ... acid plant, is investing an additional CDN$25 million in ... its stake from 30% to 40%.  Mitsui will also ... acid produced in Sarnia , providing ...
(Date:2/10/2016)... -- The Maryland House of Delegates and House Speaker ... Maryland School of Medicine Dean E. Albert Reece ... System President and CEO Robert Chrencik , MBA, ... given to the public by the leader of the ... and Mr. Chrencik for their contributions to our statewide ...
(Date:2/10/2016)... -- ASAE is introducing a hybrid membership model which ... option of joining or renewing through an organizational purchasing ... size, every employee in any size association or AMC ... available member benefits.   John H. Graham, ... will allow organizations of any size and their employees ...
(Date:2/10/2016)... (NYSE MKT: ISR), a medical technology company and innovator ... treatment of prostate, brain, lung, head and neck and ... second quarter and six months of fiscal 2016, which ... --> Revenue was $1.19 million for ... 31, 2015, a 12% increase compared to $1.07 million ...
Breaking Biology Technology:
(Date:2/3/2016)... --> --> Fourth quarter 2015:   ... compared with fourth quarter of 2014. Gross margin was 46% ... Earnings per share increased to SEK 6.39 (loss: 0.49). ... , --> --> January ... (233.6), up 1,142% compared with 2014. Gross margin was 43% ...
(Date:2/3/2016)... Feb. 3, 2016 ... of the "Emotion Detection and Recognition ... and Others), Software Tools (Facial Expression, Voice ... Users,and Regions - Global forecast to 2020" ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of that Rising Market Are you interested ... analysis forecasts revenues for checkpoint inhibitors. Visiongain,s report ... market, submarket, product and national level. Avoid ... discover what progress, opportunities and revenues those emerging ...
Breaking Biology News(10 mins):